| 20.09 14:58 | dpa-AFX: GNW-Adhoc: Ipsen's Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade |
| 16.09 14:45 | dpa-AFX: GNW-Adhoc: Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors |
| 16.09 06:48 | dpa-AFX: *RBC HEBT IPSEN AUF 'OUTPERFORM' (SECTOR PERFORM) - ZIEL 140 (129) EUR |
| 16.09 06:48 | dpa-AFX: *RBC RAISES IPSEN TO 'OUTPERFORM' (SECTOR PERFORM) - PRICE TARGET 140 (129) EUR |
| 15.09 14:45 | dpa-AFX: GNW-Adhoc: Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis |
| 26.07 12:46 | dpa-AFX: GNW-Adhoc: Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases |
| 25.07 06:58 | dpa-AFX: GNW-Adhoc: Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor |
| 11.07 07:00 | dpa-AFX: GNW-Adhoc: Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential |
| 02.07 07:00 | dpa-AFX: GNW-Adhoc: Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial |
| 07.06 07:00 | dpa-AFX: GNW-Adhoc: Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo's Tri-STAR platform |
| 06.06 14:30 | dpa-AFX: GNW-Adhoc: Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer |
| 05.06 08:00 | dpa-AFX: GNW-Adhoc: Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis |
| 02.05 07:30 | dpa-AFX: GNW-Adhoc: Ipsen appoints Keira Driansky as EVP, President of North America |
| 24.04 07:00 | dpa-AFX: GNW-Adhoc: Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance |
| 22.04 07:00 | dpa-AFX: GNW-Adhoc: Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases |
| 02.04 07:00 | dpa-AFX: GNW-Adhoc: Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors |
| 08.02 06:58 | dpa-AFX: GNW-Adhoc: Building on solid FY 2023 results, Ipsen anticipates four launches in 2024 |
| 22.01 23:00 | dpa-AFX: GNW-Adhoc: Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024 |
| 07.12 07:00 | dpa-AFX: GNW-Adhoc: Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook |
| 07.12 07:00 | dpa-AFX: GNW-Adhoc: Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC |
|
|
